% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Butt:168686,
      author       = {J. A. Butt$^*$ and R. Murugan$^*$ and T. Hippchen and S.
                      Olberg and M. van Straaten$^*$ and H. Wardemann$^*$ and E.
                      Stebbins$^*$ and H.-G. Kräusslich and R. Bartenschlager$^*$
                      and H. Brenner$^*$ and V. Laketa and B. Schöttker$^*$ and
                      B. Müller and U. Merle and T. Waterboer$^*$},
      title        = {{F}rom {M}ultiplex {S}erology to {S}erolomics-{A} {N}ovel
                      {A}pproach to the {A}ntibody {R}esponse against the
                      {SARS}-{C}o{V}-2 {P}roteome.},
      journal      = {Viruses},
      volume       = {13},
      number       = {5},
      issn         = {1999-4915},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2021-00994},
      pages        = {749},
      year         = {2021},
      note         = {#EA:F022#LA:F022#},
      abstract     = {The emerging SARS-CoV-2 pandemic entails an urgent need for
                      specific and sensitive high-throughput serological assays to
                      assess SARS-CoV-2 epidemiology. We, therefore, aimed at
                      developing a fluorescent-bead based SARS-CoV-2 multiplex
                      serology assay for detection of antibody responses to the
                      SARS-CoV-2 proteome. Proteins of the SARS-CoV-2 proteome and
                      protein N of SARS-CoV-1 and common cold Coronaviruses
                      (ccCoVs) were recombinantly expressed in E. coli or HEK293
                      cells. Assay performance was assessed in a COVID-19 case
                      cohort (n = 48 hospitalized patients from Heidelberg) as
                      well as n = 85 age- and sex-matched pre-pandemic controls
                      from the ESTHER study. Assay validation included comparison
                      with home-made immunofluorescence and commercial
                      enzyme-linked immunosorbent (ELISA) assays. A sensitivity of
                      $100\%$ $(95\%$ CI: $86-100\%)$ was achieved in COVID-19
                      patients 14 days post symptom onset with dual
                      sero-positivity to SARS-CoV-2 N and the receptor-binding
                      domain of the spike protein. The specificity obtained with
                      this algorithm was $100\%$ $(95\%$ CI: $96-100\%).$ Antibody
                      responses to ccCoVs N were abundantly high and did not
                      correlate with those to SARS-CoV-2 N. Inclusion of
                      additional SARS-CoV-2 proteins as well as separate
                      assessment of immunoglobulin (Ig) classes M, A, and G
                      allowed for explorative analyses regarding disease
                      progression and course of antibody response. This newly
                      developed SARS-CoV-2 multiplex serology assay achieved high
                      sensitivity and specificity to determine SARS-CoV-2
                      sero-positivity. Its high throughput ability allows
                      epidemiologic SARS-CoV-2 research in large population-based
                      studies. Inclusion of additional pathogens into the panel as
                      well as separate assessment of Ig isotypes will furthermore
                      allow addressing research questions beyond SARS-CoV-2
                      sero-prevalence.},
      keywords     = {SARS-CoV-2 (Other) / multiplex serology (Other)},
      cin          = {F022 / F020 / D130 / D160 / F170 / C070},
      ddc          = {050},
      cid          = {I:(DE-He78)F022-20160331 / I:(DE-He78)F020-20160331 /
                      I:(DE-He78)D130-20160331 / I:(DE-He78)D160-20160331 /
                      I:(DE-He78)F170-20160331 / I:(DE-He78)C070-20160331},
      pnm          = {316 - Infektionen, Entzündung und Krebs (POF4-316)},
      pid          = {G:(DE-HGF)POF4-316},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33923338},
      doi          = {10.3390/v13050749},
      url          = {https://inrepo02.dkfz.de/record/168686},
}